共 50 条
- [41] Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in SpainCNS DRUGS, 2022, 36 (05) : 517 - 527Gutierrez-Rojas, LuisSanchez-Alonso, SergioGarcia Dorado, MartaLopez Rengel, Paola M.
- [42] Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitusJOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 127 (02) : 170 - 180Li, HanqingXu, JiayinFan, Xiaohong
- [43] Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen. A24 months follow-up and mirror image studyEUROPEAN PSYCHIATRY, 2024, 67 : S751 - S752Romero Guillena, S. L.Sanchez-Luengo, F. GotorPlasencia Garcia de Diego, B. O.
- [44] POTENTIAL HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS OF EVERY 2-MONTHS INJECTABLE CABOTEGRAVIR plus RILPIVIRINE LONG-ACTING IMPLEMENTATION IN THE SPANISH NHS VS DAILY ORAL HIV TREATMENTSVALUE IN HEALTH, 2022, 25 (12) : S129 - S130Vallejo-Aparicio, L. A.Neches, VHernandez Novoa, B.Casado, G.Jodar, F.Pinel, M.Callejo-Velasco, D.
- [45] Experiences with long-acting injectable ART: a qualitative study among people living with HIV participating in a phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and SpainJOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19Kerrigan, D.Mantsios, A.Margolis, D.Murray, M.
- [46] A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid DependenceClinical Pharmacokinetics, 2014, 53 : 813 - 824Azmi F. NasserChristian HeidbrederRoberto GomeniPaul J. FudalaBo ZhengMark K. Greenwald
- [47] A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid DependenceCLINICAL PHARMACOKINETICS, 2014, 53 (09) : 813 - 824Nasser, Azmi F.Heidbreder, ChristianGomeni, RobertoFudala, Paul J.Zheng, BoGreenwald, Mark K.
- [48] Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I StudyCNS DRUGS, 2020, 34 (09) : 961 - 972Weiden, Peter J.Du, Yangchunvon Moltke, LisaWehr, AngelaHard, MarjieMarandi, MortezaWalling, David P.
- [49] Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I StudyCNS Drugs, 2020, 34 : 961 - 972Peter J. WeidenYangchun DuLisa von MoltkeAngela WehrMarjie HardMorteza MarandiDavid P. Walling
- [50] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06): : 849 - 862Chounta, VasilikiOverton, Edgar T.Mills, AnthonySwindells, SusanBenn, Paul D.Vanveggel, Simonvan Solingen-Ristea, RodicaWang, YuanyuanHudson, Krischan J.Shaefer, Mark S.Margolis, David A.Smith, Kimberly Y.Spreen, William R.